BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33230745)

  • 1. Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.
    Ji GW; Wang K; Xia YX; Wang JS; Wang XH; Li XC
    Ann Surg Oncol; 2021 Jul; 28(7):4018-4029. PubMed ID: 33230745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.
    Jiang M; Wu C; Zhang L; Sun C; Wang H; Xu Y; Sun H; Zhu J; Zhao W; Fang Q; Yu J; Chen P; Wu S; Zheng Z; He Y; Zhou C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
    Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study.
    Ji GW; Zhu FP; Xu Q; Wang K; Wu MY; Tang WW; Li XC; Wang XH
    EBioMedicine; 2019 Dec; 50():156-165. PubMed ID: 31735556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a gradient boosting machine to predict prognosis after liver resection for intrahepatic cholangiocarcinoma.
    Ji GW; Jiao CY; Xu ZG; Li XC; Wang K; Wang XH
    BMC Cancer; 2022 Mar; 22(1):258. PubMed ID: 35277130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
    Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
    EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer.
    Kim H; Heo MH; Kim JY
    BMC Gastroenterol; 2020 Jan; 20(1):20. PubMed ID: 31992208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
    Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
    Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer.
    Kim SR; Won HS; Yang JH; Sun S; Yim K; Hong M; Hong SA; Yoon JS; Chun SH; Kim KH; Ko YH
    Sci Rep; 2022 Feb; 12(1):1931. PubMed ID: 35121803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of machine learning methods for predicting recurrence and death after curative-intent radiotherapy for non-small cell lung cancer: Development and validation of multivariable clinical prediction models.
    Hindocha S; Charlton TG; Linton-Reid K; Hunter B; Chan C; Ahmed M; Robinson EJ; Orton M; Ahmad S; McDonald F; Locke I; Power D; Blackledge M; Lee RW; Aboagye EO
    EBioMedicine; 2022 Mar; 77():103911. PubMed ID: 35248997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
    Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
    J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery.
    Akazawa Y; Mizuno S; Fujinami N; Suzuki T; Yoshioka Y; Ochiya T; Nakamoto Y; Nakatsura T
    Sci Rep; 2019 Apr; 9(1):5925. PubMed ID: 30976046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
    Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients.
    Conci S; Ruzzenente A; Simbolo M; Bagante F; Rusev B; Isa G; Lawlor RT; Pedrazzani C; Iacono C; Guglielmi A; Scarpa A
    Updates Surg; 2020 Mar; 72(1):119-128. PubMed ID: 32020551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy.
    Mekki A; Dercle L; Lichtenstein P; Nasser G; Marabelle A; Champiat S; Chouzenoux E; Balleyguier C; Ammari S
    Eur J Cancer; 2019 Sep; 119():44-56. PubMed ID: 31415986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
    Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
    Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.